• The aim of adoptive T-cell therapy of cancer is to selectively confer immunity against tumor cells. (haematologica.org)
  • The major focus of the Department of Immunology is on Translational Immunology and its spectrum of basic research covers T cell biology, antibodies, antigen presentation and innate immunity. (immunology-tuebingen.de)
  • Furthermore, frequency of interferon-γ+ (IFN-γ+) CD8+ T cells was increased in imatinib-treated CT26 tumors than control tumors, indicating induction of antitumor immunity by imatinib. (bvsalud.org)
  • To enhance GITR Ab-mediated tumor immunity, we focused on the intratumoral route, since a tumor-localized high concentration of Ab would confer activation of only tumor-infiltrating T cells. (bvsalud.org)
  • Therefore, we hypothesized that the transfer of locally administrated Ab into tumor-draining lymph nodes (TDLNs) plays an important role in inducing an effective immunity. (bvsalud.org)
  • In fact, intratumorally or peritumorally injected Ab was detected in TDLNs, and resection of Ab-injected TDLNs significantly reduced GITR Ab-mediated systemic tumor immunity. (bvsalud.org)
  • The lymphopenic condition following autologous hematopoietic stem cell transplantation (HSCT) enhances the proliferation of T cells by engaging tumor-associated antigens, leading to the alteration of the T-cell repertoire towards antitumor immunity. (bvsalud.org)
  • Studies to antigen uptake, processing and presentation to T cells, the biology of dendritic cells and the regulation of immunity are aimed to raise our understanding of the immune reactions to tumor cells and improve immunotherapy of cancer. (universiteitleiden.nl)
  • Dijke, P. ten & Cruz, L.J. (2023), Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation, Journal of Controlled Release 357: 531-544. (universiteitleiden.nl)
  • This phase I trial assessed the safety, efficacy, and immunologic responses to minor histocompatibility antigens following nonmyeloablative allogeneic hematopoietic cell transplantation as treatment for metastatic renal cell carcinoma. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • These data demonstrate that a transplantation protocol involving only selective tumor-reactive donor T cell families is an effective immunotherapy and results in long-term survival in a mouse model of human MM. The results highlight the need to develop similar ATCT strategies for MM patients that result in enhanced survival without symptoms of GvHD. (biomedcentral.com)
  • 4 In addition, TCRs for minor histocompatibility antigens, including HA-1 and HA-2, have been transferred to donor-derived virus-specific T cells to treat patients with hematologic malignancies after allogeneic stem cell transplantation. (haematologica.org)
  • The Company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. (tscan.com)
  • The prognosis for leukemia patients who've relapsed or who have residual disease following allogeneic hematopoietic stem cell transplantation is often poor, but we believe that by targeting the minor H antigen, HA-1, through a novel T cell immunotherapy, we can potentially treat and prevent subsequent relapse," said Elizabeth Krakow, M.D., MSc. (elevate.bio)
  • Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. (sagepub.com)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) involves the infusion of stem cells following administration of high-dose chemotherapy or total body irradiation for either tumor control or to prevent solid transplant rejection. (gvhdhub.com)
  • The efficacy of allogeneic hematopoietic cell transplantation (HCT) in hematologic malignancies can in large part be attributed to a graft-versus-tumor (GVT) effect, by which the donor immune system achieves immunologic control of the tumor. (mhmedical.com)
  • BSB-1001, targeting the minor histocompatibility antigen-1 (HA-1) and part of BlueSphere's TCX-101 Program, is the first TCR-T cell therapy candidate generated using TCXpress and is in development for the treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS) in conjunction with allogeneic hematopoietic stem cell transplantation (alloSCT). (bluespherebio.com)
  • Transplantation between genetically identical individuals, i.e., members of the same species with identical histocompatibility antigens, such as monozygotic twins, members of the same inbred strain, or members of a hybrid population produced by crossing certain inbred strains. (lookformedical.com)
  • We intend to use this same platform to develop enhanced TCR-T cell therapies for our solid tumor program. (tscan.com)
  • In addition to TCX-101, BlueSphere is currently identifying a broad panel of TCRs to deploy in its first solid tumor program, which will be announced later this year. (bluespherebio.com)
  • TScan is funded to execute on upcoming anticipated milestones into 2026, by which time we expect to have duration of response data for patients treated with multiplex therapy in the solid tumor program and two-year relapse data for patients in the heme program. (tscan.com)
  • TSC-203-A0201 is TScan's fourth TCR-T cell product cleared for use in its solid tumor program. (tscan.com)
  • Solid Tumor Program: TScan remains committed to populating the ImmunoBank, its collection of therapeutic TCRs across novel and validated targets as well as different HLA types, to overcome tumor heterogeneity and address resistance that can arise from HLA loss with multiplexed therapy. (tscan.com)
  • however, the role this tumor recognition pathway plays in immunotherapy has not been explored to date. (silverchair.com)
  • The current research aims to better understand the vaccination mechanisms and develop ways to influence the suppressive environment in tumors to allow effective immunotherapy. (universiteitleiden.nl)
  • These results have high potential for immunotherapy against a broad range of tumors. (silverchair.com)
  • Because of these encouraging results, we applied the same antigenic strategy to TACA-containing glycopeptides because induction of a degenerate T cell response against this class of tumor antigens may be of great advantage in cancer immunotherapy ( 10 - 12 ). (silverchair.com)
  • More importantly, numerous researches indicate that γδ T cells exhibit broad and favorable cytotoxic activity against human tumors, which is considered to be a promising and potent candidate for tumor immunotherapy development. (creative-biolabs.com)
  • Since GvT responses involve T-cell recognition of tumor-specific peptides presented by MHC molecules [ 14 ], it may be possible to identify and select donor T cells that provide beneficial GvT responses but minimal GvHD risk. (biomedcentral.com)
  • Further, we examined the expression of immune cell-related molecules in the tumors to elucidate the differences in imatinib-mediated antitumor effects between CT26 and 3LL tumors. (bvsalud.org)
  • TCRs are molecules found on surface of T cells that can recognize tumor antigens that are degraded to small protein fragments inside tumor cells. (elevate.bio)
  • However, even in a fully HLA matched HCT, GVHD still occurs due to donor T cells directed against minor histocompatibility antigens (MiHAs), polymorphic peptides displayed on host HLA molecules. (mhmedical.com)
  • One class of non-self molecules are called antigens (short for anti body gen erators) and are defined as substances that bind to specific immune receptors and elicit an immune response. (wikidoc.org)
  • Although some antigens (Ags) can stimulate the immune response directly, T cell-dependent acquired immune responses typically require antigen-presenting cells (APCs) to present antigen-derived peptides within major histocompatibility complex (MHC) molecules. (msdmanuals.com)
  • Intracellular antigens (eg, viruses) can be processed and presented to CD8 cytotoxic T cells by any nucleated cell because all nucleated cells express class I MHC molecules. (msdmanuals.com)
  • Extracellular antigens (eg, from many bacteria) that are phagocytosed or endocytosed can be processed into peptides and complexed with surface class II MHC molecules on professional APCs, which specialize in presenting antigens to CD4 helper T (Th) cells. (msdmanuals.com)
  • Follicular dendritic cells are a distinct lineage (a different cell type than conventional dendritic cells), do not express class II MHC molecules, and therefore do not present antigen to Th cells. (msdmanuals.com)
  • An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. (lookformedical.com)
  • MIH showed the best ability to distinguish cross-immunoreactive sequence pairs from non-cross-immunoreactive pairs of variants of the hepatitis C virus hypervariable region 1 (26,883 pairwise comparisons), and Major Histocompatibility Complex (MHC) binding peptides (n=181) from non-binding peptides (n=129). (cdc.gov)
  • Transplanting only tumor reactive donor T cells that mediate a graft-versus-myeloma (GvM) but not GvHD may overcome this problem. (biomedcentral.com)
  • 1 , 2 The anti-tumor effect of DLI is mediated by donor T cells recognizing allo-antigens on the malignant cells of the recipient. (haematologica.org)
  • Donor T cells may also induce GvHD due to recognition of allo-antigens on non-malignant tissues of the patient. (haematologica.org)
  • Transfer of HSV-tk to DLI preserves the beneficial anti-tumor effect and allows in vivo elimination of donor T cells if severe GvHD occurs. (haematologica.org)
  • class II are expressed on specialized antigen-presenting cells (APCs), such as macrophages, dendritic cells, and B cells. (mhmedical.com)
  • In phase I, chemotherapy or radiotherapy as part of transplant conditioning causes host tissue damage and release of inflammatory cytokines such as TNF-α, IL-1, and IL-6, with resulting priming of host antigen-presenting cells (APCs). (mhmedical.com)
  • Cytotoxic T lymphocytes were determined as the cellular effectors of GVHD, and the key role of antigen-presenting cells (APCs) in T-lymphocyte activation was established during the following years [ 11 , 12 ]. (hindawi.com)
  • Besides the secretion of pro-inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6), the increased expression of receptor repertoire (pattern recognition receptors, PRR) on APCs, mostly macrophages and dendritic cells, occurs as a result of the release of endogenous and exogenous antigens (damage-associated molecular patterns, DAMPs, and pathogen-associated molecular patterns, PAMPs). (hindawi.com)
  • Dendritic cells in the skin act as sentinel APCs, taking up antigen, then traveling to local lymph nodes where they can activate T cells. (msdmanuals.com)
  • The roles of antigen-specificity, responsiveness to TGFβ and APC subsets in tumour-induced expansion of regulatory T cells. (imperial.ac.uk)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • Much of the curative potential of allografts is attributed to the graft-versus-tumor (GvT) response that aims to destroy residual tumor cells that persist after induction therapy and ASCT [ 5 ]. (biomedcentral.com)
  • The implication of these results would be that myeloma-specific T cell subfamilies might be positively selected from the donor inoculum and infused to myeloma patients post ASCT, to afford separation of allo- from tumor-reactive T cells without the prior need to define specific target antigens. (biomedcentral.com)
  • Targeting tumor cells or the tumor microenvironment (TME) are the two major fundamental principles for antitumor therapies. (biomedcentral.com)
  • The oncogenic communication with tumor cells and through the crosstalk of autocrine and paracrine components in almost all tumor types are responsible for this phenomenon. (biomedcentral.com)
  • Tumor-infiltrating immune cells are an important component of the TIME and are a significant predictor of cancer patients' survival. (biomedcentral.com)
  • The crosstalk between pro-tumorigenic immune cells, stromal cells, and cytokines helps to establish the pre-metastatic niche for disseminated circulatory tumor cells and facilitates metastasis. (biomedcentral.com)
  • During the tumor initiation stage, cancer cells escape from immune surveillance. (biomedcentral.com)
  • During metastasis, tumor-derived exosomes help in the requirement and arrangement of immunosuppressive immune cells for favorable premetastatic niche formation and growth of metastases. (biomedcentral.com)
  • The stromal component interacts with tumor cells in complex crosstalk to support tumor growth. (biomedcentral.com)
  • The use of CD20 as suicide gene was investigated in CMV specific T cells and in T cells genetically modified with an antigen specific T-cell receptor. (haematologica.org)
  • T-cell receptor (TCR) gene transfer is an attractive strategy for rapid in vitro generation of high numbers of antigen specific T cells. (haematologica.org)
  • Although human CD20 has previously been described as functional selection marker and suicide gene after retroviral transfer to T lymphocytes, 9 , 10 the specificities of these T cells were unknown, and therefore a potential effect of CD20 on antigen-specific T-cell functions could not be investigated. (haematologica.org)
  • In this study, we showed that cell proliferation of CT26 colon cancer and Lewis lung carcinoma (3LL) lung cancer cells was not inhibited by imatinib in vitro, although its administration significantly suppressed the growth of CT26, but not 3LL, subcutaneous tumors, and prolonged survival in CT26 tumor-bearing mice. (bvsalud.org)
  • The analysis indicates that imatinib promotes infiltration of effector T cells in tumors by upregulating expression of cytokines that recruit CD8+ T cells in the tumor microenvironment, which may lead to a strong antitumor effect. (bvsalud.org)
  • First, in a murine colon cancer model, we showed that the intratumoral delivery of Ab significantly increased the number of effector T cells infiltrated into tumors, and suppressed tumor growth more effectively than the intraperitoneal and intravenous injections did. (bvsalud.org)
  • Here, we show that natural expression of NKG2D ligands on tumors provides an effective target for some cytokine-stimulated NK cells to recognize and suppress tumor metastases. (silverchair.com)
  • The target of TSC-100 is the minor histocompatibility antigen HA-1, which is a lineage-specific antigen found on blood cells. (tscan.com)
  • A key role of the immune system is to detect tumor antigens, engage T cells, and eradicate the tumor. (elevate.bio)
  • Unlike CAR T cells that recognize only surface antigens, TCRs can recognize small protein fragments derived from intracellular and surface antigens offering a more diverse way to attack tumors. (elevate.bio)
  • These small protein fragments show up on the tumor cell surface, with another protein called major histocompatibility complex (MHC), that are recognized by the TCRs and consequently signal the body's immune system to respond to fight off and kill the tumor cells. (elevate.bio)
  • Tumor-specific TCRs can be identified and then engineered into T cells that recognize and attack various types of cancers, representing a novel approach to treating and potentially preventing disease. (elevate.bio)
  • Adoptive T cell therapy can be applied to tackling relapse of leukemia post hematopoietic stem cell transplant (HSCT) by targeting the antigens expressed only by the patient's native cells, and not by the cells from the stem cell transplant donor. (elevate.bio)
  • Therapeutic vaccination has the major advantage that the induced immune response selectively attacks tumors while leaving the healthy cells untouched. (universiteitleiden.nl)
  • The graft usually comes from a human leukocyte antigen (HLA)-matched donor and contains hematopoietic cells as well as immune cells, including T lymphocytes. (gvhdhub.com)
  • or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (lookformedical.com)
  • In the current study we show that designer glycopeptides containing the Thomsen-Freidenreich (TF) antigen (β-Gal-[1→3]-α-GalNAc- O -serine) are immunogenic in vivo and generate TF-specific CTL capable of recognizing a variety of tumor cells in vitro including a MUC1-expressing tumor. (silverchair.com)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • Soluble adult worm antigen preparation (SWAP) triggers release of cytokine IL-10 from peripheral blood mononuclear cells from both healthy and infected individuals [ 505 ], and the IL-10 then suppresses lymphoproliferative responses to SWAP by 90-100% [ 504 ]. (nanomedicine.com)
  • X-VIVO Serum-free Hematopoietic Cell Media provide nutritionally complete and balanced environments for a variety of cells including lymphokine activated killer (LAK) cells, peripheral blood lymphocytes (PBL), and tumor infiltrating lymphocytes (TIL).These media do not contain any exogenous growth factors, artificial stimulators of cellular proliferation, or undefined supplements. (lonza.com)
  • It also supports the proliferation of purified CD3+ cells isolated from peripheral blood and human tumors, and can be used to support the growth of human monocytes, macrophage cells and cell lines, PBL, granulocytes, and natural killer (NK) cells as well as the expansion of HUT-78 and related human lymphocytic cell lines. (lonza.com)
  • X-VIVO 20 - optimized to support the generation of lymphokine activated killer (LAK) cells from monocyte depleted peripheral blood lymphocytes (PBL) at high density and has also been used as a growth medium for PBL and tumor infiltrating lymphocytes (TIL). (lonza.com)
  • An immune system is a collection of mechanisms within an organism that protects against disease by identifying and killing pathogens and tumor cells. (wikidoc.org)
  • In the human immune system, T lymphocytes can be divided into two subgroups, αβ T cells and γδ T cells, based on the expressed receptor on the cell surface, among which γδ T cells are a minor subset characterized by a distinctive γδ T-cell receptor (TCR). (creative-biolabs.com)
  • Up to now, a wide range of ligands has been identified that a wide range of ligands that stimulates γδ T cells in TCR dependent and major histocompatibility complex (MHC) independent manners has been identified. (creative-biolabs.com)
  • The SE are 26- to 30-kDa proteins that bind with main histocompatibility course II substances on antigen-presenting cells and stimulate T cells bearing Vs on the receptor variable area (1, 5, 7). (insulin-receptor.info)
  • TNF activity in supernatant examples was assessed by an in Homoharringtonine vitro cytotoxicity assay with TNF-sensitive L.P3 cells (a sort present from H. Fujiwara, Biomedical Analysis Center, Osaka University Homoharringtonine or college Medical College, Osaka, Japan) as previously explained (10) with minor modifications. (insulin-receptor.info)
  • An approach known as adoptive T cell therapy, using T cell receptors, or TCRs, can overcome some of the obstacles to establishing an effective immune response to fight off the target tumor. (elevate.bio)
  • Concurrent with its use for shared antigens, BlueSphere is deploying TCXpress™ and NEOXpress™, a proprietary patient-specific neoantigen discovery platform, to develop its TCX-201 Program, which aims to identify TCRs reactive against patient-specific neoantigens. (bluespherebio.com)
  • release of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α) and interleukin 6 (IL-6), is induced by tissue damage from the conditioning regimen, activating the host innate immune system ( Fig. 16-1 ). (mhmedical.com)
  • The Company has developed and continues to build its ImmunoBank, the most extensive collection of known and novel solid tumor targets across different HLA types in the TCR field. (tscan.com)
  • One of six transplantable ascites tumors of BALB/c mice was found to become periodically resistant to cytotoxic T lymphocytes (CTL). (elsevierpure.com)
  • Since tumor-reactive lymphocytes preferentially proliferate during reconstitution of the immune system, we examined whether the priming of donor lymphocytes can strengthen the antitumor effect by HSCT in a CT26 murine colon cancer model. (bvsalud.org)
  • The infusion of non-primed and GITR Ab-primed donor lymphocytes suppressed the CT26 tumor growth, and only the primed lymphocytes eliminated tumors in all the treated mice. (bvsalud.org)
  • X-VIVO 15 - similar in composition to X-VIVO 10 but optimized for the proliferation of tumor infiltrating lymphocytes (TIL) under serum-free conditions. (lonza.com)
  • While tumor expansion, contact-dependent or independent crosstalk between tumor and TIME affects the production of various cytokines that help in the polarization of antitumor immune response in the immunosuppressive TIME. (biomedcentral.com)
  • Here we demonstrate that by using glycopeptides with high affinity for the major histocompatibility complex and glycosylated in a position corresponding to a critical T cell receptor (TcR) contact, it is possible to induce anti-TACA CTL in vivo. (silverchair.com)
  • 2012). antigens that induce airway inflammation with the release of Although many studies investigated the association between inflammatory mediators. (cdc.gov)
  • In particular, interleukin (IL)-2 or IL-12 suppressed tumor metastases largely via NKG2D ligand recognition and perforin-mediated cytotoxicity. (silverchair.com)
  • Furthermore, our recent outcomes demonstrate that this febrile reactions are connected with increased degrees of circulating interleukin-2 (IL-2), interferon (IFN), and tumor necrosis element (TNF) in rabbits. (insulin-receptor.info)
  • γδ-TCR, consisting of a γ chain and δ chain and forming a complex with CD3 subunits, mediates signal transduction into the cell by recognizing a variety of ligands and antigens. (creative-biolabs.com)
  • These data highlight the possibility that tumor-specific ATCT may lead to long-term disease-free survival without GvHD in patients with MM. (biomedcentral.com)
  • This constitutes a major tumor-suppressor mechanism regulating BCL2A1 function. (edu.au)
  • FDA clearance of our IND application for TSC-100 is an important milestone for our lead liquid tumor program as it marks the first clinical-stage product candidate to advance from our pipeline of therapies geared to treat unmet needs in major cancer indications," said David Southwell, President and Chief Executive Officer. (tscan.com)
  • Clinically, the number and size of the ulcers are the two main criteria used to divide ulcers into three forms: minor, major, and herpetiform. (medscape.com)
  • In contrast, complex aphthosis has a severe clinical course, with an almost continuous presence of minor or major ulcers. (medscape.com)
  • Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. (lookformedical.com)
  • The fine specificity of the TF-specific CTL repertoire indicates that the TcR recognize the glycosylated amino acid residue together with TF in a conventional major histocompatibility complex class I-restricted fashion. (silverchair.com)
  • The human leukocyte antigen (HLA) system is fundamental to transplant biology. (mhmedical.com)
  • PITTSBURGH, PA, February 6, 2023 - BlueSphere Bio , a T-cell receptor (TCR) T-cell therapy company developing a powerful TCR discovery platform and novel therapeutic candidates for patients with hematologic malignancies and solid tumors, today announced Keir Loiacono, Chief Executive Officer of BlueSphere Bio, will present a corporate overview at the 2023 BIO CEO & Investor Conference held in New York City, NY from February 6-9, 2023. (bluespherebio.com)
  • During the third quarter, TScan announced U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application for TSC-203-A0201, a TCR-T targeting PReferentially expressed Antigen in MElanoma (PRAME). (tscan.com)
  • Accumulating research suggests that the tumor immune microenvironment (TIME) plays an essential role in regulation of tumor growth and metastasis. (biomedcentral.com)
  • Different tumor types can also design their specific microenvironment by encouraging tumor angiogenesis and stimulating peripheral immune tolerance. (biomedcentral.com)
  • Some bacteria also shed bound antigen-antibody immune complexes [ 1737 ]. (nanomedicine.com)
  • Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (lookformedical.com)
  • About 12 days after LPC-1, a myeloma tumor, was transplanted it became resistant to lysis by allogenic CTL (anti-H-2(d)) and by CTL directed to trinitrophenyl groups or minor histocompatibility antigens. (elsevierpure.com)
  • In this regard, immune-transcriptome analyses of T cell receptor (TCR) Vβ CDR3-size and sequence is being used to characterize alloreactive versus tumor-specific T-cell responses. (biomedcentral.com)
  • The cellular and molecular nature of the TIME influences cancer progression and metastasis by altering the ratio of immune- suppressive versus cytotoxic responses in the vicinity of the tumor. (biomedcentral.com)
  • Twenty-three female UCB samples were collected from healthy mothers and analyzed for minor histocompatibility Ag HY-specific responses. (ashpublications.org)
  • The processes of tumor initiation, expansion, and metastasis are governed by the TIME, where immunosuppressive and antitumor immune crosstalk play an important role. (biomedcentral.com)
  • It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. (lookformedical.com)
  • The induction of prolonged survival and growth of allografts of either tumors or normal tissues which would ordinarily be rejected. (lookformedical.com)
  • Immunoradiometric assays show that host erythrocyte antigen is lost from adult worm tegument with a half-life of up to 45 hours in vitro and ~5 days in vivo [ 493 ]. (nanomedicine.com)
  • Of interest was the finding of an AM-dependent decreased gene expression of E6, E7 and KCNH1 both in vitro and in vivo, as well as the modulation of cytokine expression, Ki-67, and tumor growth inhibition. (bvsalud.org)
  • The Company received a brief communication from the FDA indicating that the TSC-101 IND has been placed on hold pending additional assessment of the risk of off-tumor reactivity for TSC-101. (tscan.com)
  • however, the gene expression remained unchanged in imatinib-treated or control 3LL tumors. (bvsalud.org)
  • This study evaluated the effects of AM on cell proliferation, cell cycle distribution and gene expression, including its effects on tumor growth in xenografted mice. (bvsalud.org)
  • However, the immune response to tumor antigens varies and is often insufficient to prevent tumor growth and relapse. (elevate.bio)
  • Ferry A. Ossendorp is Professor Molecular Vaccin Biology and head of the Tumor Immunology group in the department Immunology of the Leiden University Medical Centre. (universiteitleiden.nl)
  • For more than 25 years Ferry Ossendorp is investigating the immune system and cancer and is now head of the Tumor Immunology Group. (universiteitleiden.nl)
  • Mice lacking C1q or C3 show accelerated rejection of minor H disparate skin grafts and resistance to induction of tolerance. (imperial.ac.uk)
  • [10] It is less common in younger patients and in those with closer human leukocyte antigens (HLA) matches between donor and the patient. (wikipedia.org)
  • In a recent meta-analysis using greater than 100 000 subjects, the 100 RA risk loci outside the human leukocyte antigen region explained only 5.5% and 4.7% of heritability in Europeans and Asians, respectively. (nature.com)
  • BCL2A1 is an anti-apoptotic member of the BCL-2 family that contributes to chemoresistance in a subset of tumors. (edu.au)
  • TSC-101 is targeted to the lineage-specific blood cell antigen HA-2, which is a novel target for cell therapy. (tscan.com)
  • Recently the research findings from the laboratory and in experimental animals are translated to an early clinical study in which cancer patients are injected with and experimental tumor-specific peptide-conjugate vaccine. (universiteitleiden.nl)
  • Therefore, understanding the TME and its immune cell components are equally important as cancer cell characteristics for tumor eradication. (biomedcentral.com)
  • Absence of a costimulatory signal results in T-cell anergy, which is a key mechanism of peripheral immune tolerance to self-antigen in normal immunoregulation. (mhmedical.com)
  • TACA-containing glycopeptides are appealing cytotoxic T cell (CTL)-based vaccines to prevent or treat cancer because the same sugar moieties are expressed in a variety of tumors, rendering a vaccination strategy applicable in a large population. (silverchair.com)
  • Receptor de la superficie celular con actividad tirosina cinasa que se sobreexpresa en un número significativo de ADENOCARCINOMAS. (bvsalud.org)